Clearstead Advisors’s Crinetics Pharmaceuticals CRNX Stock Holding History
Bought
Maintained
Sold
Other funds holding CRNX
FCM
DCM
JT
Clearstead Advisors's CRNX Position: Q2 2026 in Review
Clearstead Advisors opened a new position in Crinetics Pharmaceuticals (CRNX) in Q2 2026: 6 shares worth $225. The stake represents ﹤0.01% of the portfolio and ranks #3175 among its holdings. This is a return to the name: Clearstead Advisors previously reported a position in CRNX as recently as Q1 2025.
Clearstead Advisors first reported a position in CRNX in Q2 2024 and has held it in 5 quarters since. The position peaked at $9.31K in Q4 2024. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.
- Clearstead Advisors held 6 shares of Crinetics Pharmaceuticals worth $225 as of Q2 2026.
- Crinetics Pharmaceuticals was a new Clearstead Advisors position in Q2 2026.
- Crinetics Pharmaceuticals made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #3175 holding.
- Clearstead Advisors first reported a position in Crinetics Pharmaceuticals in Q2 2024 and has held it in 5 quarters since.
- Clearstead Advisors's Crinetics Pharmaceuticals position peaked at $9.31K in Q4 2024.
- 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.
Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.